The one company that's going the long route (originally but maybe not by the time we're done) is Synthon. They are close to finishing up a worldwide phase III study comparing their generic Copaxone to the original.
Many of their testing sites are completed already. Now if they have good results, would the FDA insist that the others follow or if they have good results and Momenta/Mylan be the same would it be a shoe-in.
Market Data 
Markets 
AI
